News
Is GSK’s Blenrep heading for a renaissance?
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the
Saturday 23 November 2024
